Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US

Recruiting now

Conditions studied: Obstructive Hypertrophic Cardiomyopathy (oHCM)

In brief

The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice

Key facts

Study ID

NCT07557498

Run by

Bristol-Myers Squibb

People needed

362

Starts

2026-01-15

Expected to finish

2027-06-17

Last updated by the study team

2026-04-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Phase I: retrospective chart review
• For inclusion in the study, participants must meet ALL of the following criteria:
• Are an adult aged 18 or over at baseline
• Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
• Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
• Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
• Are not enrolled in any interventional clinical trial at study baseline
• Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey

You may not qualify if…

• None with the proviso that all inclusion criteria are met.

Where it is running

• Adelphi Real World — Bollington, Macclesfield, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.